Measuring Symptom Severity and Quality of Life in Mastocytosis

Polina Pyatilova; Frank Siebenhaar

doi:10.1016/j.iac.2023.04.003

Measuring Symptom Severity and Quality of Life in Mastocytosis

Immunol Allergy Clin North Am. 2023 Nov;43(4):751-762. doi: 10.1016/j.iac.2023.04.003. Epub 2023 May 21.

Authors

Polina Pyatilova¹, Frank Siebenhaar²

Affiliations

¹ Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology, Immunology and Allergology, Berlin, Germany.
² Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology, Immunology and Allergology, Berlin, Germany. Electronic address: frank.siebenhaar@charite.de.

PMID: 37758411
DOI: 10.1016/j.iac.2023.04.003

Abstract

Mastocytosis is a heterogeneous disease with a wide spectrum of signs, symptoms, and concomitant disorders, such as skin lesions, anaphylaxis, osteoporosis, gastrointestinal involvement, and organomegaly. Disease specificity for frequently reported symptoms, such as fatigue, headache, anxiety, and brain fog, is poorly defined and need to be addressed in further studies. Patients with CM and non-AdvSM are mostly affected by mast cell mediator-related symptoms, whereas in AdvSM symptoms also result from organ damage, which makes their assessment challenging. In this paper we discuss approaches currently used to measure symptom burden and QoL impairment in relation to the clinical phenotype.

Keywords: Assessment; Disease burden; Mastocytosis; Quality of life; Signs; Symptoms.

Publication types

Review

MeSH terms

Humans
Mast Cells
Mastocytosis* / diagnosis
Mastocytosis, Systemic* / diagnosis
Quality of Life